Pfenex and Alvogen announced this week that they have entered into agreements to develop and commercialize PF708, a follow-on teriparatide product referencing Forteo, for the treatment of osteoporosis, in the European Union, some countries in the Middle East and North Africa, and other territories.
Pfenex and Alvogen announced this week that they have entered into agreements to develop and commercialize PF708, a follow-on teriparatide product referencing Forteo, for the treatment of osteoporosis, in the European Union, some countries in the Middle East and North Africa, and other territories.
Subject to regulatory approval, the drug will be commercialized in the European Union and Switzerland by Theramex, in the Middle East and North Africa by SAJA, and in the remaining territories by Alvogen’s current and future commercialization partners.
Under the agreement, Alvogen will assume responsibility for the local activities carried out by Teramex, SAJA, and other commercialization partners, and will oversee clinical development, regulatory submissions, litigation, manufacturing, and commercialization activities. Pfenex may be eligible to receive a gross profit split of up to 60% on sales of the product.
Pfenex is currently awaiting regulatory approval for its drug, and in the United States, it submitted an application to the FDA for consideration in December 2018. Whereas in the European Union, subsequent-entry versions of teriparatide are regulated as biosimilars, in the United States, they are treated as follow-on products. Although many products treated as drugs by the FDA (like insulins and hormones) will be regulated as biologics beginning on March 23, 2020, teriparatide is not on the FDA’s preliminary list of products that will make that transition. Thus, the Pfenex product is expected to remain a follow-on in the US context.
As such, Pfenex has submitted an 505(b)(2) New Drug Application (NDA) rather than an abbreviated Biologics License Application for the product. A key feature of 505(b)(2) NDAs is that the pathway allows manufacturers to submit their drug products for FDA review by including data collected by the reference product sponsor, although, like the biosimilar approval pathway, the follow-on must be shown to be similar to the reference through bioanalytical testing, preclinical studies, and clinical trials.
In Pfenex’s case, it submitted a data package that included a 24-week study in 181 patients with osteoporosis. The study’s primary end point was the incidence of antidrug antibodies (ADAs) at week 24, and it found no differences in the number of patients who developed ADAs while taking the reference drug or while taking PF708.
Pfenex says that it expects to be able to launch PF708 in the United States as early as the fourth quarter of 2019.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Fuel Price Cuts in European Insulin Glargine Markets
February 14th 2025Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.